scholarly journals Metalloproteinases 1 and 3 as Potential Biomarkers in Breast Cancer Development

2021 ◽  
Vol 22 (16) ◽  
pp. 9012
Author(s):  
Angela Ximena Argote Camacho ◽  
Amanda Rocío González Ramírez ◽  
Alejandro José Pérez Alonso ◽  
Juan David Rejón García ◽  
María Auxiliadora Olivares Urbano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Tissue ◽  
Proteolytic Enzymes ◽  
Breast Cancer Diagnosis ◽  
Immunohistochemical Expression ◽  
Breast Tumorigenesis ◽  
Tissue Samples ◽  
Incidence And Mortality ◽  
Variable Group ◽  
Potential Biomarkers

Breast cancer continues to be one of the main causes of morbidity and mortality globally and was the leading cause of cancer death in women in Spain in 2020. Early diagnosis is one of the most effective methods to lower the incidence and mortality rates of breast cancer. The human metalloproteinases (MMP) mainly function as proteolytic enzymes degrading the extracellular matrix and plays important roles in most steps of breast tumorigenesis. This retrospective cohort study shows the immunohistochemical expression levels of MMP-1, MMP-2, MMP-3, and MMP-9 in 154 women with breast cancer and 42 women without tumor disease. The samples of breast tissue are assessed using several tissue matrices (TMA). The percentages of staining (≤50%–>50%) and intensity levels of staining (weak, moderate, or intense) are considered. The immunohistochemical expression of the MMP-1-intensity (p = 0.043) and MMP-3 percentage (p = 0.018) and intensity, (p = 0.025) present statistically significant associations with the variable group (control–case); therefore, expression in the tumor tissue samples of these MMPs may be related to the development of breast cancer. The relationships between these MMPs and some clinicopathological factors in breast cancer are also evaluated but no correlation is found. These results suggest the use of MMP-1 and MMP-3 as potential biomarkers of breast cancer diagnosis.

scholarly journals Invasive breast tumors are characterized by the presence of crystalline nanoparticles

2020 ◽  
Author(s):  
Elena Tsolaki ◽  
William Doran ◽  
Luca Magnani ◽  
Alessandro Olivo ◽  
Inge K. Herrmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Breast Tissue ◽  
Arterial Wall ◽  
Breast Cancer Diagnosis ◽  
Malignant Tumour ◽  
Spherical Particles ◽  
Tumour Tissue ◽  
Tissue Samples

The presence of calcification in tumours has been known for decades1. Indeed, calcified breast tissue is a fundamental criterion for early breast cancer diagnosis, indicative of malignancies2, and their appearance is used to distinguish between benign and malignant in breast biopsies3,4. However, an in-depth characterization of the nature and origin of tumour tissue calcification remains elusive5–8. Here, we report the presence of nano and micron-sized spherical particles made of highly crystalline whitlockite that are exclusively found in the arterial wall of malignant invasive tumours. By applying nanoanalytical methods to healthy, benign and malignant tumour breast tissue biopsies from patients, we show that poorly crystalline apatite can be found in all breast tissue samples, whereas spherical crystalline whitlockite particles are present only in invasive cancers, mainly in areas close to the lumen of the arterial wall. Moreover, we demonstrate that the concentration of these spherical crystalline particles increases with the grade of disease, and that their size can be related to tumour type. Therefore, our results not only provide new insight into calcification of tumour tissue, but also enable a precise, yet simple route of breast cancer diagnosis and staging.

scholarly journals Raman Microspectroscopic Investigation and Classification of Breast Cancer Pathological Characteristics

Molecules ◽  
2021 ◽  
Vol 26 (4) ◽  
pp. 921
Author(s):  
Heping Li ◽  
Tian Ning ◽  
Fan Yu ◽  
Yishen Chen ◽  
Baoping Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Tissue ◽  
Ductal Carcinoma ◽  
Ex Vivo ◽  
Principal Component ◽  
Breast Cancer Diagnosis ◽  
Mucinous Carcinoma ◽  
Classification Model ◽  
Tissue Samples ◽  
And Performance

Breast cancer is one of the major cancers of women in the world. Despite significant progress in its treatment, an early diagnosis can effectively reduce its incidence rate and mortality. To improve the reliability of Raman-based tumor detection and analysis methods, we conducted an ex vivo study to unveil the compositional features of healthy control (HC), solid papillary carcinoma (SPC), mucinous carcinoma (MC), ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC) tissue samples. Following the identification of biological variations occurring as a result of cancer invasion, principal component analysis followed by linear discriminate analysis (PCA-LDA) algorithm were adopted to distinguish spectral variations among different breast tissue groups. The achieved results confirmed that after training, the constructed classification model combined with the leave-one-out cross-validation (LOOCV) method was able to distinguish the different breast tissue types with 100% overall accuracy. The present study demonstrates that Raman spectroscopy combined with multivariate analysis technology has considerable potential for improving the efficiency and performance of breast cancer diagnosis.

scholarly journals Handheld diffuse optical breast scanner probe for cross-sectional imaging of breast tissue

2019 ◽  
Vol 12 (02) ◽  
pp. 1950008 ◽  
Author(s):  
Majid Shokoufi ◽  
Farid Golnaraghi
Keyword(s):  
Breast Cancer ◽  
Breast Imaging ◽  
Breast Tissue ◽  
Reconstruction Algorithm ◽  
Breast Cancer Diagnosis ◽  
Array Detector ◽  
Light Sources ◽  
Compact Structure ◽  
Cross Sectional

Diffuse optical spectroscopy is a relatively new, noninvasive and nonionizing technique for breast cancer diagnosis. In the present study, we have introduced a novel handheld diffuse optical breast scan (DOB-Scan) probe to measure optical properties of the breast in vivo and create functional and compositional images of the tissue. In addition, the probe gives more information about breast tissue’s constituents, which helps distinguish a healthy and cancerous tissue. Two symmetrical light sources, each including four different wavelengths, are used to illuminate the breast tissue. A high-resolution linear array detector measures the intensity of the back-scattered photons at different radial destinations from the illumination sources on the surface of the breast tissue, and a unique image reconstruction algorithm is used to create four cross-sectional images for four different wavelengths. Different from fiber optic-based illumination techniques, the proposed method in this paper integrates multi-wavelength light-emitting diodes to act as pencil beam sources into a scattering medium like breast tissue. This unique design and its compact structure reduce the complexity, size and cost of a potential probe. Although the introduced technique miniaturizes the probe, this study points to the reliability of this technique in the phantom study and clinical breast imaging. We have received ethical approval to test the DOB-Scan probe on patients and we are currently testing the DOB-Scan probe on subjects who are diagnosed with breast cancer.

scholarly journals Association between cadmium and breast cancer

Medicina ◽  
2008 ◽  
Vol 44 (6) ◽  
pp. 415 ◽  
Author(s):  
Loreta Strumylaitė ◽  
Algirdas Boguševičius ◽  
Stanislovas Ryselis ◽  
Darius Pranys ◽  
Lina Poškienė ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Tissue ◽  
Benign Tumor ◽  
Normal Breast Tissue ◽  
Cadmium Concentration ◽  
Normal Breast ◽  
Tissue Samples ◽  
Malignant Breast Tissue ◽  
Two Samples ◽  
Malignant Breast

Cadmium is a known human lung carcinogen, although some studies indicate a link between cadmium exposure and human breast cancer. The objective of this study was to assess cadmium concentration in breast tissue samples of patients with breast cancer and benign breast tumor. Material and methods. The concentration of cadmium was determined in breast tissue samples of 21 breast cancer and 19 benign tumor patients. Two samples of breast tissue from each patient, i.e. tumor and normal tissue close to tumor, were taken for the analysis. Cadmium was determined by atomic absorption spectrometry (Perkin-Elmer, Zeeman 3030). Results. In patients with breast cancer, the mean cadmium concentration was 33.1 ng/g (95% CI, 21.9– 44.4) in malignant breast tissue and 10.4 ng/g (95% CI, 5.6–15.2) in normal breast tissue (P=0.002). In patients with benign tumor, the corresponding values were 17.5 ng/g (95% CI, 8.4–26.5) and 11.8 ng/g (95% CI, 5.1– 18.5) (P=0.3144). There was a statistically significant difference in cadmium concentration between malignant and benign breast tissues (P=0.009). Conclusion. The data obtained show that cadmium concentration is significantly higher in malignant breast tissue as compared with normal breast tissue of the same women or benign breast tissue. Further studies are necessary to determine the association between cadmium concentration in malignant breast tissue and estrogen receptor level, and smoking.

Mammography use in breast cancer survivors: An administrative claims study.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 6531-6531 ◽  
Author(s):  
Kathryn Jean Ruddy ◽  
Lindsey R. Sangaralingham ◽  
Heather B. Neuman ◽  
Caprice Christian Greenberg ◽  
Rachel A. Freedman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Cancer Diagnosis ◽  
Breast Cancer Survivors ◽  
Breast Tissue ◽  
Early Stage ◽  
Breast Cancer Diagnosis ◽  
First Year ◽  
Administrative Claims ◽  
Mammography Use

6531 Background: Annual mammography is recommended to screen residual breast tissue for new cancers and recurrent disease after treatment for early stage breast cancer. This study aimed to assess mammography rates over time in breast cancer survivors. Methods: We used administrative claims data from a large U.S. commercial insurance database, OptumLabs, to retrospectively identify privately- and Medicare Advantage-insured women with operable breast cancer who had residual breast tissue after definitive breast surgery between 2006 and 2015. We required coverage for at least 13 months following surgery. For each subsequent 13-month time period, we only included women without a loss of coverage, bilateral mastectomy, metastatic breast cancer diagnosis, or non-breast cancer diagnosis. We calculated the proportion of patients who had a mammogram during each 13-month period following breast surgery. We used multivariable logistic regression to test for factors associated with mammography in the first 13 months. Results: The cohort included 26,011 women followed for a median of 2.9 years (IQR 1.9-4.6) after surgery; 63.1% were less than 65 years of age, and 74.4% were white. In their first year of follow-up, 86% underwent mammography, but by year 7, this decreased to 73%. Fewer than 1% underwent MRI instead of mammography. In multivariable analysis, mammograms were less likely during the first year after surgery among women aged < 50 years (odds ratio [OR], 0.7; 95% confidence interval [CI], 0.6 to 0.8), African Americans (OR, 0.7; 95% CI, 0.7 to 0.8), patients who underwent mastectomy (OR, 0.7; 95% CI, 0.6 to 0.7), and patients residing in the Western part of the country (OR, 0.9; 95% CI, 0.7 to 0.9). Those with 1-2 comorbidities were more likely (OR, 1.1; 95% CI 1.1-1.2) than those with none to have a mammogram during that period. Mammography use did not differ significantly by year of diagnosis (2006-2015). Conclusions: Even in an insured cohort, a substantial proportion of breast cancer survivors do not undergo annual surveillance mammography. Mammography use falls as the time from the early stage breast cancer diagnosis increases. Understanding factors associated with lack of mammographic screening may help improve survivorship care.

Developing a breast cancer tissue biobank in low and middle income countries (LMICs): A research program-based approach for improving molecular profiling.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e12585-e12585
Author(s):  
Avinash Sharma ◽  
Oluwole O. Odujoko ◽  
Olusegun Isaac Alatise ◽  
Marcia Edelweiss ◽  
Peter Ntiamoah ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Composition ◽  
Breast Tissue ◽  
Breast Cancer Incidence ◽  
Lifestyle Factors ◽  
Breast Cancer Tissue ◽  
Sub Saharan Africa ◽  
Cancer Tissue ◽  
Incidence And Mortality ◽  
Patient Reported

e12585 Background: Breast cancer incidence and mortality is increasing in LMICs especially in sub-Saharan Africa, attributed to changes in lifestyle and possible biological differences. To study putative relationships among lifestyle factors, tumor biology, and the microenvironment, we aimed to develop a breast cancer tissue biobank linked with clinicopathologic and patient reported data in this resource constrained setting. Methods: We prospectively enrolled patients undergoing mastectomy at Obafemi Awolowo University Teaching hospital in Ile-Ife, Nigeria. Pre-operatively, a locally validated survey tool assessed lifestyle factors (diet and exercise); BMI and body composition (by bioimpedence) were measured. Fresh breast tissue was frozen or preserved in 10% neutral buffered formalin, or RNA later for future metabolomic work. Immunohistochemistry (IHC) for ER/PR and HER2 status was performed and read in Nigeria by a locally-trained pathologist, and Memorial Sloan Kettering. The primary outcome was feasibility assessed by successful collection of tissue, clinicopathologic data, and survey completion. Secondary outcomes were completion rate of tumor receptor IHC compared to historic rates and concordance of local vs MSK IHC. Results: From April 2018 to June 2019, 50 patients were enrolled (49 treatment and 1 risk reduction mastectomy). Clinicopathologic, body composition, and survey data, along with breast tissue were collected from all 50 patients. Patient characteristics in table below. Receptor IHC was complete in all patients (100%) compared to a historic rate of 29% (83/286) between 2010-17. Concordance of IHC between sites was 86%, 81% and 84% for subtypes (ER/PR/HER2). Conclusions: Establishing a tissue biobank with clinicopathologic and lifestyle data using locally-adapted protocols is feasible in Nigeria. Patient enrolment is ongoing and updated data will be presented. This initiative also increased local capacity for breast tumor phenotyping, which has critical implications for improving patient care. [Table: see text]

scholarly journals Carboxypeptidase N1 is anticipated to be a synergy metrics for chemotherapy effectiveness and prognostic significance in invasive breast cancer

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Ranliang Cui ◽  
Chaomin Wang ◽  
Tiantian Li ◽  
Jialei Hua ◽  
Ting Zhao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Invasive Breast Cancer ◽  
Cox Regression ◽  
Prognostic Significance ◽  
Progression Free Survival ◽  
Poor Overall Survival ◽  
Tissue Samples ◽  
Cox Regression Analysis ◽  
Potential Biomarker ◽  
Incidence And Mortality

Abstract Background The incidence and mortality of invasive breast cancer (IBC) are increasing annually. Hence, it is urgently needed to determine reliable biomarkers for not only monitoring curative effects, but evaluating prognosis. In present study, we aim to determine the potential role of Carboxypeptidase N1 (CPN1) in IBC tissues on chemotherapeutic efficacy and poor prognosis. Methods The expression level of CPN1 in IBC tissue samples (n = 123) was quantified by tissue microarray technique and immunohistochemical staining. Moreover, sera of IBC patients (n = 34) that underwent three to five consecutive chemotherapy sessions were collected. The patients were randomly stratified into a training (n = 15) as well as a validation group (n = 19). The expression of serum CA153 and CPN1 was quantified by electrochemiluminescence and ELISA assay, respectively. Results By univariate and multivariate Cox regression analysis, we show that CPN1 expression in IBC tissues, as an independent risk factor, is related to a poor overall survival (OS) and progression-free survival (PFS) (P < 0.05). Analysis of the data revealed that CPN1 over-expression could be consistently linked to adverse clinicopathological features such as lymph node metastasis and the pathological stage (pTNM) (P < 0.05). The serum CPN1 level trajectory of individual patients generally decreased during chemotherapy. In line with these findings were changes in the follow-up ultrasonography and a consistent decrease in serum CPN1 levels. The comparison of the area under the receiver operating curves (ROC) revealed that CPN1 has a better surveillance value than CA153 in the training (AUCCPN1 = 0.834 vs. AUCCA153 = 0.724) as well as the validation set (AUCCPN1 = 0.860 vs. AUCCA153 = 0.720) when comparing cycle2 versus cycle3. Conclusions CPN1 is a suitable potential biomarker for chemotherapeutic surveillance purposes as well as being an appropriate prognostic indicator which would support an improved chemotherapy regimen.

scholarly journals Mitochondrial DNA content in paired normal and cancerous breast tissue samples from patients with breast cancer

2009 ◽  
Vol 135 (8) ◽  
pp. 983-989 ◽  
Author(s):  
Alex Xiu-Cheng Fan ◽  
Ramin Radpour ◽  
Mahdi Montazer Haghighi ◽  
Corina Kohler ◽  
Peng Xia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mitochondrial Dna ◽  
Dna Content ◽  
Breast Tissue ◽  
Tissue Samples ◽  
Mitochondrial Dna Content
Sign in / Sign up

Export Citation Format

Share Document